Lansojoy Tablet DT contains Lansoprazole 15 mg, a proton pump inhibitor indicated for the treatment of acid-related gastrointestinal conditions. Lansoprazole acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing gastric acid secretion. This mechanism provides effective relief from symptoms associated with gastroesophageal reflux disease (GERD), erosive esophagitis, duodenal and gastric ulcers, and Zollinger-Ellison syndrome. Lansojoy Tablet DT is formulated as a dispersible tablet, allowing for rapid disintegration in the oral cavity, facilitating ease of administration without the need for water. This feature is particularly beneficial for patients with swallowing difficulties. The recommended dose and duration of therapy depend on the specific condition being treated and should be determined by a healthcare professional. Common adverse effects may include headache, abdominal pain, diarrhea, nausea, and constipation, though these are generally mild and transient. Lansojoy Tablet DT should be used with caution in patients with hepatic impairment and is contraindicated in individuals with known hypersensitivity to lansoprazole or other proton pump inhibitors. Patients are advised to consult their physician before initiating therapy to ensure appropriate use and monitoring.